Partner
Danielle has been involved in all stages of district court litigation, from complaint to trial and post-trial. Her litigation experience includes analyzing patent portfolios for assertion; formulating claim construction, infringement, and validity positions; drafting discovery requests and responses; taking and defending fact and expert depositions; preparing witnesses for deposition, Markman hearings, and trial; examining expert witnesses at trial; and drafting summary judgment motions and briefs, Markman briefs, pre- and post-trial motions and briefs, findings of fact, and conclusions of law.
In addition to her litigation practice, Danielle advises clients on a variety of patent matters, including patent procurement, and pre- and post-litigation strategies.
Prior to her legal career, Danielle worked in the pharmaceutical and cosmetic industries. She worked as a research assistant at small biotechnology companies and at the W.M. Keck Center for Transgene Research at the University of Notre Dame. She also gained experience in clinical trial research by working on Phase II, III, and IV clinical trials at two major pharmaceutical companies. Danielle received her Ph.D. from McGill University, where she studied perturbed naïve T cell homeostasis and thymic abnormalities in patients with relapsing-remitting multiple sclerosis.
Danielle provides pro bono representation in immigration law. Her cases include obtaining asylum for political refugees from Rwanda and Ethiopia; one matter also entailed attaining derivative asylum for a refugee's children and permanent residency for the family. She is listed on the Capital Pro Bono High Honor Roll.
Danielle co-leads Finnegan FORWARD (Focused on Raising Women's Advancement, Representation, and Development), the firm's women's business initiative.
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
Member of trial team for Avid in suit concerning amyloid beta technology and its use in animal models in searching for drugs to treat Alzheimer's disease (AD). Obtained jury verdict for Avid on issue of inventorship and patent ownership in 2012; affirmed by the Federal Circuit in 2013. Also obtained a finding of exceptional case, entitling Avid to an award of attorneys' fees. The trial disposed of a series of suits by the AIA against numerous companies involved in scientific research relating to Alzheimer's disease.
2:10-cv-06908, E.D. Pa., Judges Angell, Savage, Cohen (Special Master)
13-1544, 16-2647, Fed. Cir., Judges Hughes, Lourie, Moore, Newman, Plager
Eli Lilly and Company v. Actavis Labs. UT Inc.
Representing Eli Lilly in Hatch-Waxman action against several defendants relating to Cialis®.
1:16-cv-01119, E.D. Va., Judges Nachmanoff, Trenga
In re Rosuvastatin Calcium Patent Litigation
Assisted appellate counsel for AstraZeneca in briefing and preparation for oral argument in action to prevent generic competition with respect to cholesterol lowering drug Crestor®. Judgment for patent owner on all issues.
1:08-md-01949, D. Del., Judges Farnan, Stark
10-1460, -1461, -1462, -1463, -1464, -1465, -1466, -1467, -1468, -1469, -1470, -1471, -1472, -1473, Fed. Cir., Judges Mayer, Newman, Plager
Cumberland Pharmaceuticals Inc. v. Mylan Institutional, LLC
Represented for Cumberland in ANDA litigation and breach of contract arbitration. Successful outcome in bench trial, arbitration, arbitration fee award, and on appeal.
16-1155, -1259, Fed. Cir., Judges Moore, Reyna, Taranto
1:12-cv-03846, N.D. Ill., Judge Pallmeyer
Duchesnay Inc. v. Actavis Laboratories FL, Inc. et al.
Represented Duchesnay in ANDA litigation in the District of Delaware against multiple generic drug manufacturers seeking to make a generic version of Bonjesta® (doxylaine succinate and phyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy.
1:18-cv-01895, D. Del., Judges Andrews, Fallon
Represented Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.
2:17-cv-10230, D.N.J., Judges Mannion, Salas
Articles
Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation
May 1, 2023
Bloomberg LawAt the PTAB Blog
Moderna’s Appeal of PTAB Decision Dismissed for Lack of Standing Moderna’s Appeal of PTAB Decision Dismissed for Lack of Standing
December 20, 2021
Articles
Ex Parte Seizure Under the Defend Trade Secrets Act: Insights on the New Remedy Ex Parte Seizure Under the Defend Trade Secrets Act: Insights on the New Remedy
April 8, 2020
Westlaw Journal Intellectual PropertyArticles
Three Years Later: How the Defend Trade Secrets Act Complicated the Law Instead of Making It More Uniform Three Years Later: How the Defend Trade Secrets Act Complicated the Law Instead of Making It More Uniform
July/August 2019
IP LitigatorBooks
Coordinating New Drug Application (NDA) and Patent Portfolio Strategy Coordinating New Drug Application (NDA) and Patent Portfolio Strategy
2018
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second EditionArticles
Impermissibly Redefining 'Long-Felt Need' Using Hindsight Impermissibly Redefining 'Long-Felt Need' Using Hindsight
March 2, 2018
Law360Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Managing Intellectual PropertyCommentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Managing Intellectual PropertyAward/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyAnnouncement
Finnegan Announces 2021 Mentors of the Year Finnegan Announces 2021 Mentors of the Year
December 28, 2021
Press Release
The National Law Journal Names Finnegan a Top Firm for Women in Law The National Law Journal Names Finnegan a Top Firm for Women in Law
July 8, 2021
The National Law JournalDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.